Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Electra Gruppen in connection with the merger with Elon Group
Mandate

Vinge advises Electra Gruppen in connection with the merger with Elon Group

December 09, 2021 EU, Competition and Regulatory Capital Markets and Public M&A

Electra Gruppen, listed on Nasdaq Stockholm, develops and operates concepts for retail chains with independent entrepreneurs, especially within consumer electronics, and is a flexible logistics partner that offers advanced IT and logistics solutions. Electra Gruppen’s merger with Elon Group creates the leading voluntary specialist retail chain in the Nordic region for home products with a focus on kitchens, appliances, consumer electronics, lighting and interior design, offered to consumers and businesses.

Based on the closing price of Electra Gruppen’s share on 6 December 2021 of SEK 65.0 per share, the value of the Electra Gruppen shares issued amounts to approximately SEK 628 million. The merger is intended to be carried out during the first half of 2022.

The Vinge team has primarily consisted of Charlotte Levin, Erik Sjöman, Amanda Knutsson, Annika Nyberg Ekenberg (Corporate public), samt Johan Karlsson, Sebastian Örndahl och Jakob Jeanrond (EU and competition).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025